PT3082773T - Formulações orais de derivados de pirrolidina - Google Patents
Formulações orais de derivados de pirrolidinaInfo
- Publication number
- PT3082773T PT3082773T PT148208143T PT14820814T PT3082773T PT 3082773 T PT3082773 T PT 3082773T PT 148208143 T PT148208143 T PT 148208143T PT 14820814 T PT14820814 T PT 14820814T PT 3082773 T PT3082773 T PT 3082773T
- Authority
- PT
- Portugal
- Prior art keywords
- oral formulations
- pyrrolidine derivatives
- pyrrolidine
- derivatives
- formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003235 pyrrolidines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13197606.0A EP2886107A1 (en) | 2013-12-17 | 2013-12-17 | Oral formulations of pyrrolydine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3082773T true PT3082773T (pt) | 2018-01-09 |
Family
ID=49765403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT148208143T PT3082773T (pt) | 2013-12-17 | 2014-12-15 | Formulações orais de derivados de pirrolidina |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20170065556A1 (OSRAM) |
| EP (4) | EP2886107A1 (OSRAM) |
| JP (2) | JP6479800B2 (OSRAM) |
| KR (1) | KR102350156B1 (OSRAM) |
| CN (2) | CN110960495B (OSRAM) |
| AU (1) | AU2014364962B2 (OSRAM) |
| CA (1) | CA2931592C (OSRAM) |
| CY (1) | CY1119728T1 (OSRAM) |
| DK (1) | DK3082773T3 (OSRAM) |
| EA (2) | EA031530B1 (OSRAM) |
| ES (2) | ES2654927T3 (OSRAM) |
| HK (1) | HK1249050B (OSRAM) |
| HU (1) | HUE035212T2 (OSRAM) |
| IL (2) | IL245855B (OSRAM) |
| MX (2) | MX363697B (OSRAM) |
| PT (1) | PT3082773T (OSRAM) |
| SI (1) | SI3082773T1 (OSRAM) |
| UA (1) | UA116824C2 (OSRAM) |
| WO (1) | WO2015091365A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| EP3753921A1 (en) | 2014-07-02 | 2020-12-23 | ObsEva S.A. | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
| TWI829098B (zh) | 2015-01-02 | 2024-01-11 | 美商梅拉洛伊卡公司 | 細菌組成物 |
| ES2915948T3 (es) | 2016-01-04 | 2022-06-27 | ObsEva SA | Administración conjunta de alfa-aminoéster de derivado de hidroxipropiltiazolidin-carboxamida y un agente tocolítico |
| WO2018015497A2 (en) * | 2016-07-21 | 2018-01-25 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| IT201600101413A1 (it) | 2016-10-10 | 2018-04-10 | Sofar Swiss S A | Composizione liquida per uso nel trattamento del reflusso gastroesofageo |
| IT201700124434A1 (it) * | 2017-10-31 | 2019-05-01 | Sofar Swiss Sa | Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali per uso nel trattamento di una sottopopolazione di pazienti GERD. |
| IT201700124424A1 (it) | 2017-10-31 | 2019-05-01 | Sofar Swiss Sa | Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali |
| GB201910125D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| GB201910116D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| EP4025207A1 (en) * | 2019-09-03 | 2022-07-13 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| AU2021218895A1 (en) | 2020-02-10 | 2022-09-15 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
| SMT202200411T1 (it) | 2020-05-18 | 2022-11-18 | Orexo Ab | Nuova composizione farmaceutica per il rilascio controllato di farmaci |
| AU2022395920A1 (en) | 2021-11-25 | 2024-05-30 | Orexo Ab | Pharmaceutical composition comprising adrenaline |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3482815A (en) | 1967-07-07 | 1969-12-09 | Victor Naturale | Collapsible core for a mold |
| YU120988A (en) * | 1988-06-23 | 1990-06-30 | Lek Tovarna Farmacevtskih | Process for preparing new dispersion pills of cimetidine |
| US4832307A (en) | 1988-09-15 | 1989-05-23 | Toshiba Kikai Kabushiki Kaisha | Injection mold |
| YU183988A (en) * | 1988-09-30 | 1990-08-31 | Lek Tovarna Farmacevtskih | Process for preparing dispersion pills of dihydroergotoxine |
| US5089043A (en) | 1989-11-09 | 1992-02-18 | Shionogi & Co., Ltd. | Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides |
| US5889001A (en) | 1993-07-29 | 1999-03-30 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| JP2869854B2 (ja) | 1994-10-19 | 1999-03-10 | 株式会社トスカ | 合成樹脂の成形方法とその装置 |
| JP3534903B2 (ja) | 1995-06-09 | 2004-06-07 | 鐘淵化学工業株式会社 | １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法 |
| GB9603699D0 (en) * | 1996-02-21 | 1996-04-17 | Boots Co Plc | Therapeutic composition |
| US6696484B2 (en) * | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| DE60027761T2 (de) * | 1999-12-09 | 2007-01-25 | Reckitt Benckiser Healthcare (Uk) Ltd., Slough | Komprimierte zubereitung enthaltend nichtsteroidale entzündungshemmer |
| ES2261404T3 (es) | 2000-03-27 | 2006-11-16 | Applied Research Systems Ars Holding N.V. | Derivados de pirrolidina utiles como inhibidores de bax. |
| DK1268418T3 (da) | 2000-03-27 | 2006-09-25 | Applied Research Systems | Farmaceutisk aktive pyrrolidinderivater som Bax-inhibitorer |
| IL157995A0 (en) | 2001-03-20 | 2004-03-28 | Applied Research Systems | The use of pyrrolidine ester derivatives in modulation of oxytoxin activity, some new such derivatives, their preparation and pharmaceutical compositions containing them |
| EP1444225B1 (en) | 2001-06-18 | 2012-10-10 | Merck Serono SA | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists. |
| JP2003192582A (ja) * | 2001-12-12 | 2003-07-09 | Merck Patent Gmbh | ナプロキセンナトリウムを含む速放性錠剤 |
| UA78058C2 (en) | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| ES2333719T3 (es) | 2003-02-27 | 2010-02-26 | Merck Serono Sa | Derivados de pirrolidina en calidad de antagonistas de oxitocina. |
| EA011026B1 (ru) | 2004-02-26 | 2008-12-30 | Лаборатуар Сероно Са | Способ получения пирролидиноксимов |
| GB2411355B (en) * | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
| KR100985449B1 (ko) * | 2005-05-10 | 2010-10-05 | 페링 인터내셔널 센터 에스 에이 | 옥시톡신 및/또는 바소프레신 길항제의 용도 |
| WO2007052289A2 (en) * | 2005-07-22 | 2007-05-10 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
| EP1978939A2 (en) * | 2005-12-27 | 2008-10-15 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine |
| JP2008189732A (ja) | 2007-02-01 | 2008-08-21 | Fujifilm Corp | セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置 |
| US20090152770A1 (en) | 2007-08-07 | 2009-06-18 | Canon Virginia Inc. | Mechanically collapsible core for injection molding |
| PT2572705T (pt) * | 2007-10-01 | 2017-11-08 | Lesvi Laboratorios Sl | Comprimidos orodispersíveis |
| US9201077B2 (en) | 2009-07-27 | 2015-12-01 | Colorado State University Research Foundation | Direct enzyme immunoassay for measurement of serum progesterone levels |
| HK1213454A1 (zh) | 2012-11-26 | 2016-07-08 | Ferring B.V. | 使用图像分析诊断子宫收缩水平的方法和系统 |
| JP5942815B2 (ja) | 2012-11-26 | 2016-06-29 | 株式会社ジェイテクト | 等速ジョイント用ブーツの成形金型 |
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| EP3753921A1 (en) | 2014-07-02 | 2020-12-23 | ObsEva S.A. | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity |
| PL3037101T3 (pl) | 2014-12-22 | 2019-06-28 | Ferring B.V. | Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu |
-
2013
- 2013-12-17 EP EP13197606.0A patent/EP2886107A1/en not_active Withdrawn
-
2014
- 2014-12-15 EA EA201691061A patent/EA031530B1/ru unknown
- 2014-12-15 CA CA2931592A patent/CA2931592C/en active Active
- 2014-12-15 JP JP2016534249A patent/JP6479800B2/ja active Active
- 2014-12-15 DK DK14820814.3T patent/DK3082773T3/en active
- 2014-12-15 WO PCT/EP2014/077767 patent/WO2015091365A1/en not_active Ceased
- 2014-12-15 ES ES14820814.3T patent/ES2654927T3/es active Active
- 2014-12-15 EP EP14820814.3A patent/EP3082773B1/en active Active
- 2014-12-15 CN CN201910736559.3A patent/CN110960495B/zh active Active
- 2014-12-15 MX MX2016007930A patent/MX363697B/es unknown
- 2014-12-15 PT PT148208143T patent/PT3082773T/pt unknown
- 2014-12-15 EA EA201892033A patent/EA201892033A3/ru unknown
- 2014-12-15 HU HUE14820814A patent/HUE035212T2/en unknown
- 2014-12-15 ES ES17188131T patent/ES2726730T3/es active Active
- 2014-12-15 US US15/104,683 patent/US20170065556A1/en not_active Abandoned
- 2014-12-15 UA UAA201606432A patent/UA116824C2/uk unknown
- 2014-12-15 SI SI201430538T patent/SI3082773T1/en unknown
- 2014-12-15 EP EP19150037.0A patent/EP3494967A1/en active Pending
- 2014-12-15 CN CN201480075770.0A patent/CN106029057B/zh active Active
- 2014-12-15 AU AU2014364962A patent/AU2014364962B2/en active Active
- 2014-12-15 EP EP17188131.1A patent/EP3266449B1/en active Active
- 2014-12-15 KR KR1020167018856A patent/KR102350156B1/ko active Active
- 2014-12-16 US US14/571,615 patent/US9962367B2/en active Active
-
2016
- 2016-05-25 IL IL245855A patent/IL245855B/en active IP Right Grant
- 2016-06-16 MX MX2019003598A patent/MX2019003598A/es unknown
-
2017
- 2017-12-28 CY CY20171101354T patent/CY1119728T1/el unknown
-
2018
- 2018-04-13 US US15/952,934 patent/US10478420B2/en active Active
- 2018-07-09 HK HK18108881.5A patent/HK1249050B/en unknown
-
2019
- 2019-01-15 IL IL264259A patent/IL264259A/en unknown
- 2019-02-06 JP JP2019019345A patent/JP2019108336A/ja active Pending
- 2019-09-12 US US16/569,065 patent/US11419851B2/en active Active
-
2022
- 2022-08-22 US US17/892,833 patent/US20230226021A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264259A (en) | Oral formulations of pyrrolidine derivatives | |
| IL274024A (en) | Oral preparations | |
| IL246377A0 (en) | Pharmaceutical preparations for oral administration | |
| IL245796B (en) | The composition for oral care | |
| IL240290A0 (en) | History of pyridazinone-amide and pharmaceutical preparations containing them | |
| ZA201506487B (en) | Therapeutic compounds and compositions | |
| IL240797A0 (en) | Defrasirox preparations for oral administration | |
| ZA201602510B (en) | Strigolactone formulations and uses thereof | |
| ZA201602198B (en) | Preparation of hydroxy-benzylbenzene derivatives | |
| EP3038465A4 (en) | Oral pharmaceutical formulation of omarigliptin | |
| SG11201510442TA (en) | Oral composition | |
| IL245700A0 (en) | Compositions for oral care | |
| IL245777A0 (en) | The vehicle for oral treatment to prevent stench | |
| SG11201509194SA (en) | Radiomitigating pharmaceutical formulations | |
| EP3046532A4 (en) | Oral care composition | |
| EP3090728A4 (en) | Oral composition | |
| ZA201604100B (en) | Gastro-retentive oral pharmaceutical compositions | |
| GB201305103D0 (en) | An oral dosage form | |
| EP3082783A4 (en) | Stable oral pharmaceutical composition | |
| GB201318813D0 (en) | Dental composition | |
| IL240741A0 (en) | Preparations for oral care | |
| HK1230071A1 (en) | Oral pharmaceutical composition | |
| TH148765B (th) | องค์ประกอบสำหรับช่องปาก | |
| AU2013902199A0 (en) | Oral composition |